Background--Roux-en-Y gastric bypass (RYGB) reduces obesity-associated comorbidities and cardiovascular mortality. RYGB improves endothelial dysfunction, reducing c-Jun N-terminal kinase (JNK) vascular phosphorylation. JNK activation links obesity with insulin resistance and endothelial dysfunction. Herein, we examined whether JNK1 or JNK2 mediates obesity-induced endothelial dysfunction and if pharmacological JNK inhibition can mimic RYGB vascular benefits.
Hence, the in vivo tissue-specific interactions between the 2 JNK isoforms deserve further investigation under physiological and pathological conditions. [12] [13] [14] JNK is also critical in the pathophysiology of cardiovascular disease. JNK2 À/À mice are protected from hypercholesterolemia-induced oxidative stress, endothelial dysfunction, 15 and atherosclerosis. 16 JNK2 may inhibit endothelial NO synthase (eNOS) by phosphorylation at Ser116 (Ser116-eNOS). 17, 18 Total JNK activation and Ser307-IRS-1 phosphorylation, which are increased in the aorta of spontaneously hypertensive rats, are associated with vascular insulin resistance. 19 Furthermore, in rat aortic rings, the JNK inhibitor SP600125 20 promotes vasodilation. 21 However, SP600125 is not JNK specific and targets other kinases. 22, 23 This drawback prompted the development of more JNK-specific inhibitors (eg, the peptide inhibitor D-JNKi-1 [D-JNK]), which more selectively blocks all JNK isoforms. 24 Two-week treatment of obese diabetic db/db mice with the L-enantiomer of D-JNK improves glucose tolerance and insulin sensitivity, increases protein kinase B (Akt) activation, and decreases Ser307-IRS-1 phosphorylation in liver, fat, and muscle. 25 Moreover, D-JNK treatment exerts neuroprotective effects in mouse models of cerebral ischemia, and the compound is in preclinical trials. 26 RYGB decreased total JNK activation and Ser307-IRS-1 inhibitory phosphorylation in the liver of type 2 diabetic rats 2 weeks after surgery. 27 We previously showed, in obese rats, a rapid improvement of endothelial function after RYGB. 8 In the aorta, RYGB decreased total JNK phosphorylation and oxidative stress and activated the Akt/eNOS signaling pathway, improving NO bioavailability, independent of body weight loss. 8 Therefore, the present study tested if pharmacological JNK inhibition in vivo in obese rats mimics the protective endothelial effects of RYGB. Moreover, the specific contribution of vascular JNK1 versus JNK2 in obesity-induced endothelial dysfunction and in its improvement after RYGB was investigated.
Methods
An expanded description of the methods is available in Data S1. The data, analytic methods, and study materials will be made available on request of other researchers for purposes of reproducing the results or replicating the procedure.
Antibodies and Reagents
The following commercially available antibodies were used: JNK1/2 (R&D Systems, Minneapolis, MN); phosphorylated JNK1/2 (Thr183/Tyr185) (Santa Cruz Biotechnology, Dallas, TX); IRS-1 and phosphorylated IRS-1 (Ser307), Akt and phosphorylated Akt (Ser473), protein kinase A (PKA) and phosphorylated PKA (Thr197), cAMP response element binding protein and phosphorylated cAMP response element
Clinical Perspective
What Is New?
• In a rodent model of diet-induced obesity, c-Jun N-terminal kinase 2 (JNK2), but not JNK1, phosphorylation was specifically increased in the aorta.
• Roux-en-Y gastric bypass surgery restored obesity-induced vascular dysfunction by blunting JNK2-vascular activation.
• Aortic inhibition of the JNK isoform 2 after Roux-en-Y gastric bypass was associated with improved insulin and glucagonlike peptide-1-mediated endothelium-dependent vasorelaxation as a result of preserved NO bioavailability and blunted oxidative stress.
• In vivo treatment with 2 different JNK inhibitors improved endothelium-mediated vasodilation and decreased aortic JNK2 phosphorylation, thus mimicking the effect of Roux-en-Y gastric bypass.
What Are the Clinical Implications?
• Our data suggest that novel drugs that selectively blunt JNK2 activation without the downsides of available JNK inhibitors may become a promising therapeutic option against obesity-induced endothelial dysfunction and its associated cardiovascular disease.
• It will be important to assess the vascular and metabolic effects of a combination therapy of Roux-en-Y gastric bypass and JNK inhibition.
• It is intriguing to hypothesize that, as a result of such dual treatment, a higher increase in circulating glucagon-like peptide-1 and/or in other gut hormones may synergistically potentiate the benefits observed in the present experiments.
binding protein (Ser133), protein kinase C (PKC) 
Animals and Experimental Procedures
Male Wistar rats were fed chow (lean non-operated on agematched controls, n=6) or a high-fat high-cholesterol diet to induce obesity (60% kcal fat and 1.25% cholesterol; n=46) for 7 weeks before and after surgery. 8 Obese rats were randomized to RYGB or sham surgery, and all procedures were performed as described. 8 Treatments started on the day after surgery. A pilot (proof-of-concept) study and a main experiment were performed with the 2 JNK inhibitors most commonly used for in vivo investigations. 20, 24 In the pilot study, sham-operated rats received SP600125, 40 mg/kg per day SC (SP600125, n=8), or vehicle dimethyl sulfoxide sc (control DMSO , n=6 
Organ Chamber Experiments
The thoracic aorta was cut into 2-to 3-mm-long rings and connected to an isometric force transducer (Multi-Myograph 610M; Danish Myo Technology A/S, Aarhus, Denmark), suspended in an organ chamber filled with 6 mL KrebsRinger bicarbonate solution (37°C, pH 7.4, 95% O 2 , 5% CO 2 ). Isometric tension was recorded continuously, as previously described. 8, 15 After a 30-minute equilibration period, rings were gradually stretched to reach the optimal point of their length-tension curve, as determined by the contraction in response to potassium chloride (100 mmol/L). During submaximal contraction to norepinephrine (3910 À6 mol/L), concentration-relaxation curves were obtained in a cumulative manner in response to insulin (10
and GLP-1 (7-36) amide (10 À12 to 10 À6 mol/L). 28, 29 Responses to insulin and GLP-1 were recorded in the presence or absence of Nx-nitro-L-arginine methyl ester 
Western Blot Analysis
Frozen aortas were pulverized and dissolved in lysis buffer: 
Results
In Vivo Pharmacological JNK Inhibition Improves Obesity-Induced Endothelial Dysfunction Similar to RYGB Aortic relaxation in response to GLP-1 and insulin improved similarly after D-JNK and RYGB when compared with obese control D-TAT animals ( Figure 1A and 1B). Vasodilation was abolished by preincubation with the eNOS inhibitor Nx-nitro-Larginine methyl ester, indicating an endothelial NO-dependent mechanism ( Figure S1A and S1B). Beforehand, we showed that in lean non-operated age-matched and chow-fed male Wistar rats, D-JNK did not alter GLP-1's and insulin's baseline vasodilatory effects compared with vehicle-treated controls ( Figure S1C and S1D). Results after D-JNK treatment strengthened the findings of the pilot experiment ( Figure S1E and S1F), in which rats receiving the JNK inhibitor SP600125 also improved vascular relaxation, although the effect was less pronounced than after RYGB. In Vivo JNK Inhibition and RYGB Reduce Aortic JNK2 Phosphorylation Induced by Obesity
Next, we assessed the specific contribution of the 2 vascular JNK isoforms in obesity-induced endothelial dysfunction. Phosphorylation of JNK2, but not of JNK1, increased in aortas of obese control D-TAT when compared with chow-fed lean D-TAT rats ( Figure 2A ). Furthermore, aortic JNK2 phosphorylation was significantly decreased in RYGB and D-JNK-treated rats compared with obese control D-TAT rats, whereas JNK1 phosphorylation was not affected ( Figure 2B ). A similar result was obtained after the pilot treatment with SP600125 ( Figure S2A ).
JNK Inhibition Restores Vascular Insulin-and GLP-1-Dependent Akt/eNOS/NO Pathway Similar to RYGB
The vascular Akt/eNOS signaling, which is activated by insulin and GLP-1 8, 28 and inhibited by JNK, 11, 17 was assessed by
Western blotting in aortic lysates. The JNK-dependent inhibitory Ser307-IRS-1 phosphorylation decreased comparably after RYGB and D-JNK ( Figure 2C ), whereas the activatory AktSer473 phosphorylation increased ( Figure 2D ). This led to enhanced phosphorylation of the activatory eNOS-Ser1177 ( Figure 3A ), a favorable dimer/monomer ratio of eNOS (Figure 3B ), which is essential for the proper coupling and function of the enzyme. 30, 31 Finally, it augments NO production, as assessed by increased aortic cGMP levels ( Figure 3C ). In vivo SP600125 treatment also protected the insulin-and GLP-1-dependent vascular signaling pathway, leading to preserved NO bioavailability ( Figure S2B through S2E). The phosphorylation of Ser116 is a putative JNK2 target for the inhibition of eNOS. 17, 18 However, its assessment was inconclusive because of lack of specificity of the commercially available anti-phosphorylated Ser116-eNOS antibody in rat aortic tissue ( Figure S3 ). Additional players able to modulate vascular insulin resistance, [32] [33] [34] such as PKC (a/b, b II, and d; Figure S4A through S4C) and extracellular signal regulated kinase 1/2 (p44 and p42; Figure S4E ), were assessed. No difference in phosphorylation was observed between controls and rats after RYGB or JNK inhibition, which further supports the role of reduced aortic JNK2 phosphorylation as a crucial mediator of the vascular benefits of RYGB. Only the phosphorylation of p38 MAPK was increased on JNK inhibition and unchanged in control and RYGB rats ( Figure S4D ), which may be a potential off-target effect of long-term systemic in vivo D-JNK treatment.
JNK Inhibition Reduces Vascular Oxidative Stress Similar to RYGB
JNK enhances vascular oxidative stress, which, in turn, reduces NO bioavailability and leads to endothelial dysfunction. 35, 36 Decreased oxidative stress after RYGB protects endothelial function. 
GLP-1 Contributes to Vascular JNK2 Inhibition After RYGB
Increased circulating GLP-1 contributes to the beneficial cardiovascular effects of RYGB. 8, 9 GLP-1-dependent PKA activation inhibits JNK1 and JNK2 in various tissues, including the endothelium, 34, 37 where it also activates the Akt/eNOS pathway. 38, 39 In line with our previous results, 8 fasting plasma GLP-1 levels were increased after RYGB ( Figure 4B) . Surprisingly, D-JNK treatment also increased GLP-1 levels compared with control D-TAT rats, although to a lesser extent than RYGB ( Figure 4B ). By contrast, SP600125 did not affect circulating GLP-1 levels ( Figure S5C ). The aortic expression of the GLP-1 receptor was up-regulated in RYGB and D-JNK rats. This was accompanied downstream by enhanced phosphorylation of the PKA isoform C-a at Thr197 and of the cAMP response element binding protein at Ser133 ( Figure 4C through 4E), which lie upstream of JNK1 and JNK2 inhibition. 34, 37 To further ascertain the role of GLP-1 in modulating JNK2 phosphorylation after RYGB, we analyzed aortas from our previous study, in which shamoperated on rats were treated with the GLP-1 analogue liraglutide and RYGB rats received the GLP-1 receptor antagonist exendin-9 for 8 days after surgery. 8 JNK2 phosphorylation remained high in RYGB rats on GLP-1 receptor blockade, whereas liraglutide treatment in sham-operated on rats decreased JNK2 phosphorylation. JNK1 phosphorylation was unchanged in all groups ( Figure 5A ). These results suggest that vascular JNK2 inactivation may contribute to the GLP-1-dependent improvement of endothelial dysfunction seen after RYGB. 8 In line with previous results, 8 RYGB reduced food intake and body weight ( Figure 5B and 5C). D-JNK treatment affected food intake and body weight similar to RYGB ( Figure 5B and 5C), whereas SP600125 had no effect on these 2 parameters compared with its vehicle ( Figure S6A and S6B). Non-operated chow-fed rats treated for 8 days with D-TAT and D-JNK did not show differences in body weight between the 2 groups ( Figure S6C ). This difference between the 2 JNK inhibitors prompted additional investigations to assess potential toxicity associated with the pharmacological treatment ( Figure S7 ), as described in Data S1.
Discussion
JNKs link metabolic to cardiovascular disease. 8, 12, 14, 15, 17, 18 The novel findings of this study show that RYGB via GLP-1-dependent signaling improves obesity-induced endothelial dysfunction by specific inhibition of aortic JNK2 phosphorylation. We provide the following key observations: (1) obesity specifically increased JNK2, but not JNK1, phosphorylation in the aorta; (2) RYGB improved endothelial function via a specific decrease of aortic JNK2 phosphorylation; (3) in vivo pharmacological JNK inhibition rapidly mimics this beneficial vascular effect; and (4) on lower JNK2 phosphorylation, the insulin-and GLP-1-dependent Akt/eNOS signaling was restored, oxidative stress was decreased, and aortic NO bioavailability was preserved. The major results and proposed underlying mechanisms are summarized in Figure 6 .
RYGB Reduces Aortic JNK2 Phosphorylation Induced by Obesity and Protects Endothelial Function
Studies using tissue-specific gene targeting in mice pointed initially to JNK1 12, 14 and later to JNK2 13 as pivotal players in the pathophysiological characteristics of obesity and type 2 diabetes mellitus. Hence, the role of the 2 isoforms in the overall JNK activity in metabolic disease is yet unclear. JNK2 À/À mice were protected against hypercholesterolemiainduced endothelial dysfunction 15 and atheroma formation, 16 which may suggest a specific contribution of JNK isoform 2 in the pathophysiological characteristics of atherosclerotic disease. We and others described also the association between total JNK activation and endothelial dysfunction induced by obesity 8, 40 and type 2 diabetes mellitus 41 ; however, the role of JNK1 versus JNK2 has not yet been elucidated in this context. Our study shows that in obesity, enhanced aortic-specific JNK2 phosphorylation impairs the insulin/IRS-1-and GLP-1/ GLP-1 receptor-dependent Akt/eNOS/NO pathway, leading to endothelial dysfunction, whereas JNK1 phosphorylation remains unchanged. Indeed, RYGB reduces JNK2 hyperphosphorylation and, thus, preserves the common insulin-and GLP-1-mediated Akt/eNOS-dependent NO production and restores endothelial function. 29 RYGB-mediated specific JNK2
inhibition was associated with decreased aortic Ser307-IRS-1 phosphorylation. To date, the inhibitory Ser307-IRS-1 phosphorylation has been linked to total JNK activity in the context of hepatic insulin resistance. 12 Only one study in spontaneously hypertensive rats linked Ser307-IRS-1 phosphorylation to aortic insulin resistance as a result of total JNK increased activity, with no further investigations on JNK isoform specificity. 19 
In Vivo Inhibition of JNK Mimics the Endothelial Protective Effects of RYGB
In vivo treatment with 2 different JNK inhibitors improved endothelium-mediated vasodilation and decreased aortic JNK2 phosphorylation. Activation of the intracellular Akt/eNOS signaling led to higher NO production, thus mimicking the effect of RYGB. D-JNK treatment decreased weight loss and food intake equally to RYGB; however, body weight loss per se is not sufficient to improve endothelial function, as previously shown in sham-operated rats whose body weight loss was matched to RYGB by food restriction. 8 We observed that in rats that were body weight matched to RYGB rats, endothelial dysfunction persisted and was associated with increased total JNK phosphorylation at the aortic level. 8 Furthermore, the pilot study showed that the favorable impact of SP600125 on endothelial function can also be achieved in the absence of body weight loss or reduced eating, suggesting a specific vascular benefit on pharmacological JNK inhibition. In addition, short-term ex vivo D-JNK treatment improved vasodilation of aortas of control D-TAT rats but had no incremental benefit in animals receiving long-term in vivo D-JNK treatment. These or liraglutide, 0.2 mg/kg BID sc (controls -lira ), and Roux-en-Y gastric bypass-operated on rats treated with vehicle (RYGB) or exendin -9 , 10 lg/kg per hour (RYGB -exe9 ), for 8 days. Tissues were taken from rats of a previous study on day 8 after surgery or after the start of treatment, respectively 8 (determined by 1-way ANOVA and Bonferroni post hoc test; n=8-13 per group). Cumulative 24-hour food intake (determined by 2-way ANOVA and Bonferroni post hoc test; n=8-13 per group; (B) and body weight (C) of control D-TAT , RYGB, and peptide inhibitor D-JNKi-1 (D-JNK) rats before and after surgery and start of treatment (day 0) (no differences, determined by 2-way repeated measures ANOVA and Bonferroni post hoc test; n=8-13 per group). Results are shown as meanAESD. p indicates phosphorylated. *P<0.05 and **P<0.01 for RYGB vs controls or RYGB -exe9 ; ***P<0.001 for RYGB vs control D-TAT ; &&& P<0.001 for RYGB vs D-JNK;°°°D-JNK vs control D-TAT .
findings support a JNK inhibitory effect directly exerted in the aortas to complement other systemic beneficial metabolic effects of in vivo D-JNK treatment. 25, 42 JNKs promote reactive oxygen species production, which impairs NO bioavailability and leads to endothelial dysfunction. 15, 36 In agreement with our previous findings, 8 the preincubation of aortic rings with the radical scavenger superoxide dismutase improved insulin-and GLP-1-mediated relaxations of aortas in control D-TAT rats but not in RYGB and D-JNK treated rats. This result confirms the reduction of vascular oxidative stress, as shown by the reduced O À 2 levels and NADPH oxidase activity, 35 in the aortas of RYGB and D-JNK rats. In microvascular endothelial cells, NADPH-dependent increase of reactive oxygen species after hypoxia/ reoxygenation was blunted by SP600125 and by dominantnegative JNK1, whereas the role of JNK2 in that condition had not been investigated in detail. 43 Our findings suggest that in the aorta, obesity may specifically induce NADPH oxidase via JNK2, rather than JNK1, activation.
GLP-1-Dependent Inhibition of Aortic JNK2 Restores Endothelial Function After RYGB
Finally, the present study focused on the role of upstream GLP-1-dependent molecular pathways in mediating aortic JNK2 inactivation after RYGB. In line with our previous results, 8 fasting plasma GLP-1 levels and aortic GLP-1 receptor expression were increased after RYGB. GLP-1-dependent aortic PKA Thr197 and cAMP response element binding protein Ser133 activatory phosphorylations were increased and accompanied by downstream JNK2 inhibition, thus strengthening the mechanistic link between increased GLP-1 signaling after RYGB and aortic JNK2 inhibition. This notion was supported by the fact that in vivo GLP-1 receptor antagonism with exendin-9 in RYGB rats blocked the JNK2 inhibition achieved by RYGB, whereas GLP-1 agonism with liraglutide tended to mimic the benefit of RYGB in obese sham-operated on rats.
p-JNK2
GLP-1
• Interestingly, systemic administration of D-JNK also increased circulating GLP-1 levels; this was not observed with SP600125, possibly because of its lower potency and specificity. 23 Peripheral GLP-1 is secreted from intestinal endocrine cells in response to nutrients 44 and insulin. 45 Therefore, JNK inhibition in the small intestine may influence GLP-1 secretion through the insulin signaling. Hence, systemic JNK inhibition may improve endothelium-mediated vasodilation through a direct inactivation of vascular JNK2, and indirectly through increased GLP-1 signaling, which may further contribute to blunt JNK2 and to activate eNOS in aortas, as summarized in Figure 6 . In future studies, it would, therefore, be important to assess the vascular and metabolic effects of a combination therapy between RYGB and JNK inhibition in comparison to the single treatment reported in the present study. It is intriguing to hypothesize that, as a result of such dual treatment, higher increases in circulating GLP-1 and/or in other gut hormones may synergistically potentiate the benefits observed in the present experiments.
Study Limitations
Reduced JNK2-dependent inhibitory phosphorylated Ser116-eNOS may have contributed to the observed benefits of RYGB and JNK inhibition, 17, 18 but lack of specificity of the commercially available antibodies in the rat aorta did not allow a satisfactory assessment of this putative JNK2 target. SP600125 inhibits multiple other kinases besides JNK, 23 which limits its clinical application. On the other hand, D-JNK treatment, despite a high JNK specificity, 24 may induce renal toxicity, in particular in obese animals, which seems attributable to its carrier peptide, D-TAT, and thus is independent of the D-JNK inhibitory activity, as previously shown. 46 Indeed, we observed proximal tubule injury in the carrier peptide-treated control D-TAT and in D-JNK rats. In a previous study, despite improved glucose control, albuminuria worsened after in vivo treatment with the peptide JNK inhibitor in diabetic db/db mice 42 by an effect possibly linked to the D-TAT carrier peptide-induced kidney toxicity, independent of the metabolic benefits of JNK inhibition. 42, 46 In our study, SP600125 treatment was not associated with kidney injury, further supporting the presence of JNK-independent cytotoxicity (ie, toxicity related to the D-TAT carrier peptide). 46 Last, in D-JNK treated rats, aortic phosphorylation of p38 MAPK was increased, in contrast to previous in vitro studies testing D-JNK specificity. 26, 47 Although potential off-target effects of long-term systemic in vivo D-JNK administration cannot be excluded, in our setting, this treatment led to overall improved aortic Akt/eNOS signaling and NO bioavailability. Overall, our data suggest that novel drugs, able to selectively blunt JNK2 activation without the downsides of available JNK inhibitors, may become a promising therapeutic option against obesity-induced endothelial dysfunction and its associated cardiovascular disease.
Conclusions
Obesity-induced activation of vascular JNK2 and the associated endothelial dysfunction were reversed by RYGB, through GLP-1-dependent signaling. These beneficial effects of RYGB were mimicked by in vivo pharmacological JNK inhibition, highlighting the potential therapeutic relevance of novel strategies targeting vascular JNK2 against the severe cardiovascular disease associated with obesity.
Data S1

Tissue harvesting and blood collection
Rats were sacrificed eight days after surgery and start of treatment. Rats were fasted overnight and sacrificed at the beginning of the light cycle by isoflurane anesthesia followed by heart exsanguination. For plasma analyses, blood collected in Microvette EDTA vacutainers was supplemented with a DPPIV inhibitor; for serum analyses, blood was collected in Microvette vacutainers. After centrifugation, plasma or serum were stored at -80°C. Organs were harvested within 30 minute after exsanguination. The thoracic aorta was placed immediately in cold modified KrebsRinger bicarbonate solution (pH 7.4, 37°C, 95% O2, 5% CO2) of the following composition (mmol/L): NaCl (118.6), KCl (4.7), CaCl2 (2.5), KH2PO4 (1.2), MgSO4 (1.2), NaHCO3 (25.1), glucose (11.1), and calcium EDTA (0.026). The aorta was cleaned from adhering connective tissue and was either snap-frozen in liquid nitrogen and stored at -80°C or used immediately for ex vivo organ chamber experiments.
Dihydroethidium staining on rat aortae
Frozen 10 µm sections from aortae were cut with a Leica CM3050S cryostat and placed on positive-charged slides Superfrost Plus. Dihydroethidium (DHE) was prepared as stock solution in DMSO, diluted in deoxygenated PBS (final concentration 5 µM), and applied to frozen sections for 30 min at 37°C. Nuclei were counterstained with Hoechst 33258 (final concentration 1µg/ml). Slides were coverslipped and images taken on a SP8 microscope (10x/0.30 objective; Leica, Solms, Germany), and quantified (ImageJ, NIH). DHE fluorescence was calculated by subtracting the auto-fluorescence signal (green channel) from the DHE signal (red channel), and normalized to the total fluorescent area.
qPCR analysis
Expression of kidney injury molecule-1 (KIM-1) and lipocalin-2 (NGAL) was analyzed by qPCR of snap-frozen kidney tissue. RNA was isolated from frozen kidneys with a RNaeasy Mini Kit and reverse transcribed with a Ready-To-Go YouPrime First-Strand Beads. Rat-specific primers were used for KIM-1 (forward:
GTGGGTCACCCTGTCACAAT, reverse: ATGTTGTATCGACCGCTGCT) and NGAL (forward: GATGAACTGAAGGAGCGATTC, reverse:
TCGGTGGGAACAGAGAAAAC). CT results were normalized to GAPDH CT.
Histological analysis
Representative samples of aorta, liver, pancreas, kidneys, thyroid glands, inguinal white adipose tissue and interscapular brown adipose tissue were fixed in 10% neutral buffered formalin and embedded in paraffin. Sections (3-5 µm) were prepared, mounted on glass slides, deparaffinised in xylene, rehydrated through graded alcohols and stained with haematoxylin and eosin (H&E) for the histological examination. All slides were scanned using digital slide scanner NanoZoomer-XR C12000 (Hamamatsu, Hamamatsu City, Japan) and images were taken using NDPview2 viewing software (Hamamatsu). 
Supplemental Results
JNK2 inhibition after in vivo SP600125 treatment induces protective vascular effects similar to RYGB
In the pilot experiment, eight-day treatment of DIO sham-operated ad libitumfed rats with SP600125 increased endothelium-mediated relaxation in response to GLP-1 and insulin similar to RYGB, although the effect was less pronounced than in RYGB rats (Fig. S1E-F) . In vivo SP600125 treatment decreased aortic JNK2 phosphorylation compared to controls DMSO rats, while JNK1 phosphorylation was not affected (Fig. S2A ). JNK2 inhibition was followed by decreased IRS-1 Ser307 and increased Akt Ser473 phosphorylation and higher eNOS dimerization similar to RYGB and D-JNK treatment ( Fig. S2B-E) . Additionally, in vivo SP600125 treatment also decreased aortic superoxide anion levels and NADPH activity comparable to RYGB surgery ( Fig. S5A-B) . SP600125 did not affect circulating GLP-1 levels (Fig. S5C) . These results support a direct role of vascular JNK2 inactivation in lowering oxidative stress and activating Akt/eNOS signaling pathways to improve endothelial function after RYGB, and prompted us to perform the main experiment using the more specific JNK inhibitor D-JNK.
Aortic eNOS Ser116 phosphorylation
It has been published that JNK2 directly inhibits eNOS by Ser116 phosphorylation in studies using bovine aortic endothelial cells 1 and mouse aortae 2 .
Unfortunately, we could not detect eNOS Ser116 phosphorylation in rat aorta with the same anti-human Ser116 antibody used in previous publications 1, 2 . This antibody, which is the only commercially available anti-phospho-Ser 116 eNOS, showed bands between 100 kDa and 130 kDa, but not at 140 kDa, which is the expected molecular weight of eNOS. In contrast, total eNOS was detected at 140 kDa (Fig. S3) 
D-TAT carrier peptide-dependent kidney toxicity
D-JNK treatment affected food intake and body weight similar to RYGB (Fig.6B-C) , while SP600125 or D-JNK in chow-fed lean rats (Fig. S6A-C ) had no effect. This prompted us to investigate organ toxicity as a potential cause of weight loss after chronic D-JNK treatment in obese rats. Circulating markers of liver and kidney damage were assessed (urea, creatinine, cystatin C, transferrin, albumin, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase). Only creatinine and cystatin C levels were significantly elevated in the D-JNK group, suggesting potential kidney toxicity ( Fig. S6D-E) . Furthermore, histological analysis indicated tubular degeneration and necrosis, accompanied by tubular regeneration and interstitial, predominantly lymphohistiocytic cell infiltration ( Fig.   S7A-B) . Renal injury also occurred in controls D-TAT rats but was more moderate (approximately 40% tubules affected) compared to D-JNK-treated rats (> 80%).
These histological changes were accompanied by impaired kidney function in controls D-TAT and D-JNK animals, with increased urinary excretion and a presumably compensatory higher water intake ( Fig. S7C-F Results are shown as mean ± SD. Figure S5C where results are presented as median ± IQR. 
